More studies are needed to determine whether FSCN1 has value as a biomarker in the most relevant cancers, over biomarkers that are in current clinical use, and whether targeting FSCN1 with small molecules will be useful for cancer therapy. The gene discussed is FSCN1; the disease is cancer.